Brought to you by 
Nanomedicine firm Bind Therapeutics nets $65.6mm in IPO
27 Sep 2013
Executive Summary
In the same year that the biotech signed its first three major partnerships involving its core Accurin platform, seven-year-old Bind Therapeutics Inc. (targeted and programmable nanomedicines) netted $65.6mm in its initial public offering of 4.7mm shares for $15, the mid-point of its anticipated $14-16 range.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nanomedicine firm Bind Therapeutics nets $65.6mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice